Acurx CEO granted 37,100 stock options
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.
The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.
Insider Trade Summary
Grant/Award: 37,100 shares
Grant/Award
1 txn
Insider
LUCI DAVID P
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 37,100 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 37,100 contracts (Direct)
Footnotes (1)
- F1. On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Key Figures
Options granted: 37,100 options
Exercise price: $2.36 per share
Vesting schedule: 36 monthly installments
+2 more
5 metrics
Options granted
37,100 options
Grant to CEO on April 20, 2026
Exercise price
$2.36 per share
Stock option grant strike price
Vesting schedule
36 monthly installments
Vesting begins on April 20, 2026
Expiration date
April 20, 2036
Stock options expiry
Options held after grant
37,100 options
Total stock options following transaction
Key Terms
Stock Option, Grant Date, vest, exercise price, +1 more
5 terms
Stock Option financial
"the Reporting Person was granted stock options to purchase 37,100 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Grant Date financial
"On April 20, 2026 (the "Grant Date"), the Reporting Person was granted"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest financial
"These options vest in 36 equal monthly installments commencing on the Grant Date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "2.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-04-20T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Acurx Pharmaceuticals (ACXP) report for David P. Luci?
Acurx Pharmaceuticals reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was awarded options covering 37,100 shares of common stock, structured as a compensation-related grant rather than an open-market share purchase or sale.
How many stock options did the Acurx (ACXP) CEO receive in this Form 4?
The CEO received stock options for 37,100 shares of Acurx common stock. Each option relates to one underlying share, and the entire 37,100 options are shown as held directly after the transaction, reflecting this single grant reported in the Form 4 filing.
What is the exercise price of the Acurx (ACXP) stock options granted to the CEO?
The stock options granted to the CEO have an exercise price of $2.36 per share. This means he can choose to purchase Acurx common stock at $2.36 for each option, subject to the vesting schedule and the April 20, 2036 expiration date.
When do the Acurx Pharmaceuticals (ACXP) CEO’s new stock options vest?
The CEO’s new stock options vest in 36 equal monthly installments starting on April 20, 2026. This monthly vesting structure gradually makes portions of the 37,100 options exercisable over three years, aligning the grant with ongoing service to the company.
When do the Acurx (ACXP) stock options granted to the CEO expire?
The stock options granted to the CEO expire on April 20, 2036. He can exercise vested portions of the 37,100 options at $2.36 per share any time before this expiration date, subject to the company’s equity plan and applicable rules.
Is the Acurx (ACXP) CEO’s Form 4 transaction a market buy or sell?
The Form 4 reflects a grant of stock options, not an open-market buy or sell of shares. The transaction is coded as an acquisition related to compensation, giving the CEO the right to purchase 37,100 shares at $2.36 per share over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
